Recurrent BCOR internal tandem duplication and BCOR or BCL6 expression distinguish primitive myxoid mesenchymal tumor of infancy from congenital infantile fibrosarcoma

• Published in: Modern pathology Vol. 30; no. 6; pp. 884 - 891
• Main Authors: Santiago, Teresa, Clay, Michael R, Allen, Sariah J, Orr, Brent A
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2017; Elsevier Limited
• Subjects: Age; Bcl-6 protein; Biomarkers, Tumor - analysis; Biomarkers, Tumor - genetics; Cell Nucleus - chemistry; Central nervous system; Children; Chronic lymphocytic leukemia; Diagnosis, Differential; Feet; Female; Fibrosarcoma; Fibrosarcoma - chemistry; Fibrosarcoma - congenital; Fibrosarcoma - pathology; Humans; Immunohistochemistry; Immunoreactivity; Infant; Infant, Newborn; Infants; Lymphocytes B; Lymphoma; Male; Mesenchyme; Polymerase Chain Reaction; Predictive Value of Tests; Proto-Oncogene Proteins - analysis; Proto-Oncogene Proteins - genetics; Proto-Oncogene Proteins c-bcl-6 - analysis; Repressor Proteins - analysis; Repressor Proteins - genetics; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms - chemistry; Soft Tissue Neoplasms - genetics; Soft Tissue Neoplasms - pathology; Stroma; Tandem Repeat Sequences; Tumor Burden; Tumor cells; Tumors
• ISSN: 0893-3952; 1530-0285
• DOI: 10.1038/modpathol.2017.12

Primitive myxoid mesenchymal tumor of infancy is a rare sarcoma that preferentially affects infants. It can be locally aggressive and rarely metastasizes, but the long-term outcome of children with this tumor is mostly unknown. Histologically, it is characterized by primitive cells with abundant myxoid stroma. Internal tandem duplication of B-cell CLL/lymphoma 6 (BCL6)-interacting co-repressor (BCOR) exon 15 has recently been described in clear cell sarcoma of kidney, central nervous system high-grade neuroepithelial tumor with BCOR alteration, and primitive myxoid mesenchymal tumor of infancy. Herein, we report five cases of primitive myxoid mesenchymal tumor of infancy: three girls and two boys with mean age of 6.5 months. The tumors were located in the paraspinal region (n=3), back (n=1), or foot (n=1) and ranged in size from 2.5 to 10.2 cm. BCOR internal tandem duplication was confirmed by PCR and sequencing in all five cases. The minimally duplicated region consisted of nine residues, which is shorter than was previously reported in other BCOR-associated tumors. To assess the clinical value and specificity of the BCOR internal tandem duplication, a group of 11 ETV6-rearranged congenital infantile fibrosarcomas were evaluated and no BCOR internal tandem duplication was identified in any case. Though not detected in congenital infantile fibrosarcomas, BCOR and BCL6 immunoreactivity was present in >90% of the nuclei of tumor cells in each of the five primitive myxoid mesenchymal tumor of infancy. The presence of BCOR internal tandem duplication in all five primitive myxoid mesenchymal tumors of infancy provides evidence that it is a recurrent somatic abnormality and substantiates the concept that this tumor is a unique sarcoma of infancy. Our findings indicate that identification of BCOR internal tandem duplication and/or nuclear immunoreactivity for BCOR or BCL6 can aid in the diagnosis of primitive myxoid mesenchymal tumor of infancy and help to differentiate it from congenital infantile fibrosarcoma.